Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Aarnoutse

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Plos One|March 15, 2019
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centreCharlotte Seijger, Wouter Hoefsloot, Inge Bergsma-de Guchteneire, et al.
International Journal of Antimicrobial Agents|August 17, 2016
Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patientsVycke Yunivita, Sofiati Dian, Ahmad Rizal Ganiem, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicinAllan Kengo, Kamunkhwala Gausi, Ruth Nabisere, et al.
Tuberculosis (Edinburgh, Scotland)|January 27, 2015
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacyGerjo J de Knegt, Marian T ten Kate, Dick van Soolingen, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicinAllan Kengo, Ruth Nabisere, Kamunkhwala Gausi, et al.
Tuberculosis (Edinburgh, Scotland)|November 27, 2014
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacyGerjo J de Knegt, Marian T Ten Kate, Dick van Soolingen, et al.
Antibiotics (Basel, Switzerland)|January 25, 2025
Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of AgeAntoni Noguera-Julian, Emma Wilhelmi, Maria Cussó, et al.
Tropical Medicine & International Health : TM & IH|August 4, 2018
A treatment-support intervention evaluated in South African paediatric populations with HIV infection or tuberculous meningitisSabine L van Elsland, Remco P H Peters, Maarten O Kok, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 31, 2021
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokineticsMike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, et al.
Open Forum Infectious Diseases|October 9, 2025
Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysisAndrea Llamas-Lopez, James A Seddon, Felicia C Chow, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Plos One|March 15, 2019
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centreCharlotte Seijger, Wouter Hoefsloot, Inge Bergsma-de Guchteneire, et al.
International Journal of Antimicrobial Agents|August 17, 2016
Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patientsVycke Yunivita, Sofiati Dian, Ahmad Rizal Ganiem, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicinAllan Kengo, Kamunkhwala Gausi, Ruth Nabisere, et al.
Tuberculosis (Edinburgh, Scotland)|January 27, 2015
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacyGerjo J de Knegt, Marian T ten Kate, Dick van Soolingen, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicinAllan Kengo, Ruth Nabisere, Kamunkhwala Gausi, et al.
Tuberculosis (Edinburgh, Scotland)|November 27, 2014
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacyGerjo J de Knegt, Marian T Ten Kate, Dick van Soolingen, et al.
Antibiotics (Basel, Switzerland)|January 25, 2025
Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of AgeAntoni Noguera-Julian, Emma Wilhelmi, Maria Cussó, et al.
Tropical Medicine & International Health : TM & IH|August 4, 2018
A treatment-support intervention evaluated in South African paediatric populations with HIV infection or tuberculous meningitisSabine L van Elsland, Remco P H Peters, Maarten O Kok, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 31, 2021
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokineticsMike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, et al.
Open Forum Infectious Diseases|October 9, 2025
Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysisAndrea Llamas-Lopez, James A Seddon, Felicia C Chow, et al.
Pageof 7